Compare VIOT & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | TTRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 116.0M |
| IPO Year | 2018 | N/A |
| Metric | VIOT | TTRX |
|---|---|---|
| Price | $1.41 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 277.9K | 14.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | $3.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $2.57 |
| 52 Week High | $4.33 | $5.98 |
| Indicator | VIOT | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 48.74 |
| Support Level | $1.22 | $3.55 |
| Resistance Level | $1.49 | $4.01 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 75.00 | 41.18 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.